We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Precision Analyzer Reveals ‘Chameleon Proteins’ Causing Intractable Diseases

By LabMedica International staff writers
Posted on 17 Mar 2026

Understanding how proteins behave inside the body is essential for uncovering the causes of many complex diseases. More...

While most proteins function based on stable three-dimensional structures, a large portion of human proteins lack a fixed shape, making them extremely difficult to study. Researchers have now developed a new analytical method that can precisely examine these elusive proteins, opening new possibilities for understanding and treating diseases such as dementia, Parkinson’s disease and diabetes.

The advanced protein analysis technique, developed by a joint research team from the Daegu Gyeongbuk Institute of Science and Technology (DGIST, Daegu, South Korea) and the Korea Basic Science Institute (KBSI, Daejeon, South Korea), combines artificial intelligence (AI), computer simulations and experimental validation to study intrinsically disordered proteins. Approximately one-third of human proteins are intrinsically disordered proteins, meaning they do not have a fixed three-dimensional structure and constantly change their shape. Despite their unstable nature, these proteins play critical roles in cellular signaling and regulation. However, when they misfold or aggregate abnormally, they are closely linked to neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease, as well as metabolic conditions like type 2 diabetes.

To study these proteins, the researchers developed a hybrid analytical approach. First, they generated tens of thousands of possible protein structures using artificial intelligence models, advanced simulations, and structural data from the Protein Data Bank. These candidate structures were then compared with real experimental data obtained through nuclear magnetic resonance spectroscopy. Using a “maximum entropy” method, the system assigned higher confidence to structures that closely matched experimental observations. This approach enabled the researchers to capture even short-lived intermediate structures that occur during protein movement, allowing for a more accurate representation of how these proteins behave in real biological conditions.

The ability to observe intrinsically disordered proteins at the atomic level represents a significant advancement in biomedical research. By tracking how these proteins change under different conditions, such as temperature variations or genetic mutations, researchers can better understand how misfolding processes contribute to disease development. The findings, published in Proceedings of the National Academy of Sciences (PNAS), could play a crucial role in identifying disease mechanisms and designing targeted therapies for conditions that have long been difficult to treat due to the complex nature of these proteins.

The research team plans to expand this approach by developing dedicated structural databases for disordered proteins. In collaboration with national research institutions, they aim to establish a localized version of the Protein Data Bank focused on proteins without fixed structures. Such resources could accelerate research into previously inaccessible protein behaviors and support the development of new treatments for neurodegenerative and metabolic diseases.

“By unraveling the structural secrets of amorphous proteins, which were previously impossible to analyze, we expect this to become a crucial analytical tool for understanding the pathogeneses of intractable diseases, such as dementia, and for developing treatments to control them,” said DGIST Professor Yoo Wookyung.

Related Links:
DGIST
KBSI


New
Gold Member
Pre- Eclampsia Control
Acusera Pre-Eclampsia Control
Online QC Software
Acusera 24•7
Urine Analyzer
respons® UDS100
Thyroid Test
Anti-Thyroid EIA Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The approach supports myocardial infarction diagnosis in resource-limited settings by reducing delays between clinical suspicion and biochemical confirmation (Image Credit: Adobe Stock)

Portable Troponin Assay Brings Heart Attack Diagnosis Closer to Patients

Timely confirmation of myocardial infarction often depends on laboratory testing that may not be immediately available at the point of care. This gap between clinical suspicion and definitive evidence... Read more

Microbiology

view channel
Image: An innovative countywide program in Taiwan combines risk-based screening with decentralized community care to improve hepatitis C detection and treatment (Image Credit: iStock)

Precision Screening Helps Close Hepatitis C Diagnosis and Treatment Gaps

Hepatitis C remains a leading cause of cirrhosis and liver cancer, yet many infections go undiagnosed or untreated because health systems fail to reach those at greatest risk. Although highly effective... Read more

Pathology

view channel
Image: Through the PCCP, Proscia gains a more efficient pathway to expand Concentriq AP-Dx interoperability while maintaining regulatory oversight (Photo courtesy of Proscia)

FDA-Cleared Digital Pathology Platform Expands Interoperability for Primary Diagnosis

Rising cancer incidence is colliding with a shrinking pathologist workforce, intensifying pressure on diagnostic turnaround times in clinical laboratories. Many labs are adopting digital pathology to manage... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.